The drugmaker says a shift towards specialty medicines and branded generics has structurally improved its profitability, even as competition intensifies in the US generics business.
The drugmaker says a shift towards specialty medicines and branded generics has structurally improved its profitability, even as competition intensifies in the US generics business.